Summary: In a post hoc mediation analysis pooling adults with obesity or overweight (with or without type 2 diabetes) from the SURMOUNT-1 to -4 Phase 3 trials, gastrointestinal adverse events were more frequent with tirzepatide (27.8% to 72.8%) than placebo (12.2% to 32.5%), yet weight reduction was similar whether participants reported no nausea, nausea alone, or any nausea, vomiting or diarrhoea. Mediation analyses estimated that these events accounted for only up to 3.1% of total weight reduction, suggesting gastrointestinal side effects are not the main driver of the weight loss.
PICO Summary
| Element | Detail |
|---|---|
| Population | Adults with obesity or overweight, with or without type 2 diabetes, pooled across the four global Phase 3 SURMOUNT-1 to -4 randomised trials (post hoc analysis); baseline characteristics were similar between those who did and did not report gastrointestinal adverse events. |
| Intervention | Once-weekly subcutaneous tirzepatide (5, 10 or 15 mg, per trial protocol), administered with dose escalation. |
| Comparison | Once-weekly placebo. The primary contrast of interest in this analysis was within-tirzepatide: participants reporting no nausea/vomiting/diarrhoea versus nausea alone versus any nausea/vomiting/diarrhoea. |
| Outcome | Gastrointestinal adverse events occurred in 27.8% to 72.8% of tirzepatide arms versus 12.2% to 32.5% of placebo arms; most were non-serious and clustered during dose escalation. Weight reduction was similar across nausea categories. Mediation analyses estimated nausea/vomiting/diarrhoea and dyspepsia accounted for up to 3.1% of total weight reduction. Treatment discontinuation due to gastrointestinal adverse events ranged from 1.0% to 10.5% across tirzepatide arms. No formal hypothesis-test p-values or confidence intervals for the mediation estimate are reported in the abstract. |
Expert Commentary
This post hoc, pooled analysis of the SURMOUNT programme addresses a question that is often raised in clinic: does tirzepatide work mainly by making people feel too unwell to eat? The data argue against that. Weight reduction was comparable whether participants reported no nausea, nausea alone, or any nausea, vomiting or diarrhoea, and mediation modelling attributed at most 3.1% of total weight loss to these symptoms. The pharmacological effect therefore appears to dominate, with gastrointestinal intolerance a minor contributor rather than the engine of benefit. The verdict is that this is a reassuring, internally consistent finding, though it must be read as associational and exploratory: a post hoc mediation analysis cannot establish causation, and self-reported symptoms are imperfectly captured. The weighed limitation worth flagging is sponsorship and authorship, since the study was funded by the manufacturer (Eli Lilly) and most authors are company employees, which warrants cautious interpretation of a conveniently reassuring conclusion. The trials were placebo-controlled and double-blind, which strengthens the underlying comparisons. Can I use this with my patients? Yes, for counselling: a person hesitant to start tirzepatide because they fear weight loss depends on feeling sick can be told the benefit does not hinge on nausea, and that symptoms are usually transient and tied to dose escalation. The wish is for an independent replication of the mediation estimate with reported confidence intervals.
References
Rubino DM, Pedersen SD, Connery L, Cao D, Chigutsa F, Stefanski A, et al. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes Obes Metab. 2025;27(4):1826-1835. doi:10.1111/dom.16176